Answers are grounded in this paper and cite their sources.
Demonstrates that endovascular stroke therapy combined with standard care is cost-effective across most subgroups, highlighting uncertainty for patients with low ASPECTS or M2 occlusions.
EVT+SC is cost-effective in most subgroups. In patients with ASPECTS ≤5 or with M2 occlusions, cost-effectiveness remains uncertain based on current data.
No takes yet. Share an insight, caveat, or question.
Kunz et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: